Omnicell, Inc. — Earnings Quality Grade C
OMCL · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 67 days, change -17 days YoY
AR growth -15.4% vs revenue growth 6.5%
Revenue 6.5%, CFFO -32.2%. Cash follows revenue
Expense Quality
Inventory 13.8% vs COGS 6.3%. Normal
CapEx growth 9.7% vs revenue 6.5%. Normal
SG&A/Gross Profit = 81.4%, exceeds 70%
Gross margin 42.5%, change +0.1pp. Stable
Cash Flow Quality
CFFO far exceeds NI (ratio 62.0x). Non-cash charges depressing profits
FCF $0.1B, FCF/NI = 33.80
Accruals ratio = -6.3%. Low accruals
Cash $0.2B covers debt $0.2B
Balance Sheet Health
Goodwill+Intangibles $1.0B = 78% of equity. Over 50%
Debt/EBITDA = 2.2x. Healthy
Other assets 2.6% vs revenue 6.5%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -2% YoY. Normal
Manipulation Score
M-Score = -2.85 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor OMCL continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25